NCT06772766View on ClinicalTrials.gov

A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Beta-Thalassemia
Interventions
DRUG

9MW3011

Ascending IV doses administered per protocol

DRUG

9MW3011 placebo

Ascending IV doses administered per protocol

Trial Locations (2)

530021

RECRUITING

The first Affiliated Hospital of Guangxi Medical University, Nanning

570311

RECRUITING

Hainan General Hospital, Haikou

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY